Chemical constituents from a marine medicinal brown alga-derived Xylaria acuta SC1019

In this study, a marine medicinal brown alga Sargassum cristaefolium-derived fungal strain Xylaria acuta SC1019 was isolated and identified. Column chromatography of the extracts from liquid-and solid-fermented products of the fungal strain was carried out, and led to the isolation of twenty-one compounds. Their structures were characterized by spectroscopic analysis, and the absolute configurations were further established by single X-ray diffraction analysis or modified Mosher's method as nine previously undescribed compounds, namely xylarilactones AeC (1e3), ent-gedebic acid 8-O- α -D-glucopyranoside (4), 5R-hydroxylmethylmellein 11-O- α -D-glucopyranoside (5), ent-hymatoxin E 16-O-α-D-mannopyranoside (6), 19,20-epoxycytochalasin S (7), 19,20-epoxycytochalasin T (8), and (2R)-butylitaconic acid (9), along with twelve known compounds 10e21. All the isolates were subjected to anti-inflammatory and anti-angiogenic assays. Compounds 1, 5, 7, 10, and 17 showed moderate nitric oxide production inhibitory activities in lipopolysaccharide-activated BV-2 microglial cells with IC₅₀ values of 19.55 ± 0.35, 16.10 ± 0.57, 15.20 ± 0.87, 11.76 ± 0.49, and 11.30 ± 0.32 μM, respectively, as compared to curcumin (IC₅₀ = 2.69 ± 0.34 μM) without any significant cytotoxicity. Compounds 7, 8, and 21 displayed potent anti-angiogenic activities by suppressing the growth of human endothelial progenitor cells with IC₅₀ values of 0.44 ± 0.01, 0.47 ± 0.03, and 0.53 ± 0.01 μM, respectively, as compared to sorafenib (IC₅₀ = 5.50 ± 1.50 μM).